Scholarlink

<p>This study aims to assess the clinical efficacy of continuous glucose monitoring (CGM) in postoperative glycemic management for patients undergoing pancreatic resection, and to determine whether CGM can reduce postoperative complications and enhance recovery quality. This prospective study included 83 patients with pancreatic malignancy who underwent pancreatic resection from January 2023 to December 2024. Patients were divided into two groups: the CGM group (<i>n</i> = 41) and the control group (<i>n</i> = 42) using conventional fingertip blood glucose monitoring. Both groups received perioperative glycemic management. Data were analyzed using SPSS 29.0 and R 4.3.1, with propensity score matching (PSM) at a 1:1 ratio to balance covariates such as age, BMI, diabetes history, and surgical type. After propensity score matching, the CGM group (<i>n</i> = 33) demonstrated significantly lower postoperative mean blood glucose levels (7.76 ± 1.58&#xa0;mmol/L vs.11.06 ± 3.11&#xa0;mmol/L, <i>p</i> &lt; 0.001) and smaller glycemic variability (3.43 ± 1.40&#xa0;mmol/L vs. 8.51 ± 3.94&#xa0;mmol/L, <i>p</i> &lt; 0.001) compared to the controls (<i>n</i> = 33). No significant differences were observed in complications except for shorter postoperative hospitalization in the CGM group (14&#xa0;days vs. 17&#xa0;days, <i>p</i> = 0.048). The incidence of pancreatic fistula was lower in the CGM group (9.1% vs .21%, <i>p</i> = 0.133), although this did not reach statistical significance. CGM offers significant advantages in postoperative glycemic management for patients undergoing pancreatic resection by lowering blood glucose levels, reducing fluctuations, and shortening postoperative hospital stay duration. There is a potential possibility to reduce postoperative complications. Further multicenter randomized controlled trials are needed to confirm the long-term benefits of CGM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Continuous Glucose Monitoring: Enhancing Precision Care and Economic Value Beyond Fingerstick Testing in Post-Pancreatectomy Metabolic Management

  • 期刊论文

  • 发表日期：

    2025年7月29日

查看全文
  • Yaoqi Zhang,
  • Liying Zhang,
  • Gang Li,
  • Can Lin,
  • Bo Zhuang,
  • Shian Yu

摘要

This study aims to assess the clinical efficacy of continuous glucose monitoring (CGM) in postoperative glycemic management for patients undergoing pancreatic resection, and to determine whether CGM can reduce postoperative complications and enhance recovery quality. This prospective study included 83 patients with pancreatic malignancy who underwent pancreatic resection from January 2023 to December 2024. Patients were divided into two groups: the CGM group (n = 41) and the control group (n = 42) using conventional fingertip blood glucose monitoring. Both groups received perioperative glycemic management. Data were analyzed using SPSS 29.0 and R 4.3.1, with propensity score matching (PSM) at a 1:1 ratio to balance covariates such as age, BMI, diabetes history, and surgical type. After propensity score matching, the CGM group (n = 33) demonstrated significantly lower postoperative mean blood glucose levels (7.76 ± 1.58 mmol/L vs.11.06 ± 3.11 mmol/L, p < 0.001) and smaller glycemic variability (3.43 ± 1.40 mmol/L vs. 8.51 ± 3.94 mmol/L, p < 0.001) compared to the controls (n = 33). No significant differences were observed in complications except for shorter postoperative hospitalization in the CGM group (14 days vs. 17 days, p = 0.048). The incidence of pancreatic fistula was lower in the CGM group (9.1% vs .21%, p = 0.133), although this did not reach statistical significance. CGM offers significant advantages in postoperative glycemic management for patients undergoing pancreatic resection by lowering blood glucose levels, reducing fluctuations, and shortening postoperative hospital stay duration. There is a potential possibility to reduce postoperative complications. Further multicenter randomized controlled trials are needed to confirm the long-term benefits of CGM.